Ligand Pharmaceuticals Incorporated $LGND reported second-quarter 2026 revenue of $63.7 million, down 24.2% from a year ago but slightly ahead of the $62.5 million estimate. Gross profit came in at $60.5 million, while operating profit edged up to $8.6 million.
Net income attributable to common shareholders rose sharply to $48.5 million, or $2.22 per diluted share, compared with the prior-year period. Operating cash flow also improved, reaching $24.0 million.
The company ended the quarter with $115.1 million in cash and cash equivalents. On the balance sheet, total liabilities were $1.2 billion.
- Revenue: $63.7 million
- Net income: $48.5 million
- Diluted EPS: $2.22
- Operating cash flow: $24.0 million
- Cash and equivalents: $115.1 million
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Ligand Pharmaceuticals Incorporated Insider Trading Activity
Ligand Pharmaceuticals Incorporated insiders have traded $LGND stock on the open market 91 times in the past 6 months. Of those trades, 0 have been purchases and 91 have been sales.
Here’s a breakdown of recent trading of $LGND stock by insiders over the last 6 months:
- ANDREW REARDON (CLO & Secretary) has made 0 purchases and 49 sales selling 30,000 shares for an estimated $7,341,193.
- OCTAVIO ESPINOZA (Chief Financial Officer) has made 0 purchases and 12 sales selling 16,480 shares for an estimated $3,450,647.
- JASON HAAS has made 0 purchases and 2 sales selling 6,461 shares for an estimated $1,651,320.
- JOHN L LAMATTINA has made 0 purchases and 5 sales selling 6,752 shares for an estimated $1,585,616.
- JASON ARYEH has made 0 purchases and 2 sales selling 5,000 shares for an estimated $1,250,000.
- STEPHEN L SABBA has made 0 purchases and 3 sales selling 5,179 shares for an estimated $1,162,553.
- JOHN W KOZARICH has made 0 purchases and 18 sales selling 3,435 shares for an estimated $751,152.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Ligand Pharmaceuticals Incorporated Hedge Fund Activity
We have seen 193 institutional investors add shares of Ligand Pharmaceuticals Incorporated stock to their portfolio, and 156 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CONGRESS ASSET MANAGEMENT CO added 155,274 shares (+30.8%) to their portfolio in Q2 2026, for an estimated $49,080,558
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 150,696 shares (-41.4%) from their portfolio in Q1 2026, for an estimated $30,086,456
- NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO removed 146,265 shares (-99.9%) from their portfolio in Q1 2026, for an estimated $29,201,807
- BLACKROCK, INC. added 139,073 shares (+4.7%) to their portfolio in Q2 2026, for an estimated $43,959,584
- JACOBS LEVY EQUITY MANAGEMENT, INC removed 106,225 shares (-83.8%) from their portfolio in Q1 2026, for an estimated $21,207,821
- NEXT CENTURY GROWTH INVESTORS LLC added 95,876 shares (+inf%) to their portfolio in Q1 2026, for an estimated $19,141,643
- BESSEMER GROUP INC added 84,349 shares (+358.8%) to their portfolio in Q1 2026, for an estimated $16,840,277
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Ligand Pharmaceuticals Incorporated Congressional Stock Trading
Members of Congress have traded $LGND stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $LGND stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 05/29, 03/03 and 0 sales.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
Ligand Pharmaceuticals Incorporated Price Targets
Multiple analysts have issued price targets for $LGND recently. We have seen 6 analysts offer price targets for $LGND in the last 6 months, with a median target of $285.5.
Here are some recent targets:
- Jason Zemansky from B of A Securities set a target price of $388.0 on 07/09/2026
- Annabel Samimy from Stifel set a target price of $332.0 on 07/08/2026
- Douglas Miehm from RBC Capital set a target price of $262.0 on 05/08/2026
- Joseph Pantginis from HC Wainwright & Co. set a target price of $289.0 on 04/30/2026
- Yigal Nochomovitz from Citigroup set a target price of $282.0 on 04/15/2026
- Trevor Allred from Oppenheimer set a target price of $277.0 on 02/27/2026
